Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2025-12-25 @ 6:57 PM
Study NCT ID:
NCT05139004
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-08
First Post:
2021-11-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-19
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-13
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-13
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-22
First Submit QC Date:
None
Study First Post Date:
2021-12-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-01
Last Update Post Date:
2025-07-08
Last Update Post Date Type:
ACTUAL